2′- and 3′-Ribose Modifications of Nucleotide Analogues Establish the Structural Basis to Inhibit the Viral Replication of SARS-CoV-2
KAUST DepartmentComputational Bioscience Research Center (CBRC), Computer, Electrical and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal, 23955-6900, Saudi Arabia
Computer Science Program
Computational Bioscience Research Center (CBRC)
Computer, Electrical and Mathematical Science and Engineering (CEMSE) Division
Embargo End Date2023-05-03
Permanent link to this recordhttp://hdl.handle.net/10754/676679
MetadataShow full item record
AbstractInhibition of RNA-dependent RNA polymerase (RdRp) by nucleotide analogues with ribose modification provides a promising antiviral strategy for the treatment of SARS-CoV-2. Previous works have shown that remdesivir carrying 1'-substitution can act as a "delayed chain terminator", while nucleotide analogues with 2'-methyl group substitution could immediately terminate the chain extension. However, how the inhibition can be established by the 3'-ribose modification as well as other 2'-ribose modifications is not fully understood. Herein, we have evaluated the potential of several adenosine analogues with 2'- and/or 3'-modifications as obligate chain terminators by comprehensive structural analysis based on extensive molecular dynamics simulations. Our results suggest that 2'-modification couples with the protein environment to affect the structural stability, while 3'-hydrogen substitution inherently exerts "immediate termination" without compromising the structural stability in the active site. Our study provides an alternative promising modification scheme to orientate the further optimization of obligate terminators for SARS-CoV-2 RdRp.
CitationLi, Y., Zhang, D., Gao, X., Wang, X., & Zhang, L. (2022). 2′- and 3′-Ribose Modifications of Nucleotide Analogues Establish the Structural Basis to Inhibit the Viral Replication of SARS-CoV-2. The Journal of Physical Chemistry Letters, 4111–4118. https://doi.org/10.1021/acs.jpclett.2c00087
SponsorsFinancial support from the National Key R&D program of China (2021YFA1502300), the National Natural Science Foundation of China (21733007), and the NSFC/RGC Joint Research Scheme 2020/2021 (N_HKUST635/20). This research made use of the resources of the Supercomputing Laboratory at King Abdullah University of Science & Technology (KAUST).
PublisherAmerican Chemical Society (ACS)
- 1'-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication.
- Authors: Zhang L, Zhang D, Wang X, Yuan C, Li Y, Jia X, Gao X, Yen HL, Cheung PP, Huang X
- Issue date: 2021 Mar 14
- A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
- Authors: Jockusch S, Tao C, Li X, Anderson TK, Chien M, Kumar S, Russo JJ, Kirchdoerfer RN, Ju J
- Issue date: 2020 Aug
- Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
- Authors: Seifert M, Bera SC, van Nies P, Kirchdoerfer RN, Shannon A, Le TT, Meng X, Xia H, Wood JM, Harris LD, Papini FS, Arnold JJ, Almo S, Grove TL, Shi PY, Xiang Y, Canard B, Depken M, Cameron CE, Dulin D
- Issue date: 2021 Oct 7
- Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
- Authors: Shannon A, Le NT, Selisko B, Eydoux C, Alvarez K, Guillemot JC, Decroly E, Peersen O, Ferron F, Canard B
- Issue date: 2020 Jun
- Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
- Authors: Chien M, Anderson TK, Jockusch S, Tao C, Li X, Kumar S, Russo JJ, Kirchdoerfer RN, Ju J
- Issue date: 2020 Nov 6